Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study

por Kelley, R. K., Verslype, C., Cohn, A. L., Yang, T.-S., Su, W.-C., Burris, H., Braiteh, F., Vogelzang, N., Spira, A., Foster, P., Lee, Y., Van Cutsem, E.
Publicado 2017

A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

por Kelley, R.K., Gane, E., Assenat, E., Siebler, J., Galle, P.R., Merle, P., Hourmand, I.O., Cleverly, A., Zhao, Y., Gueorguieva, I., Lahn, M., Faivre, S., Benhadji, K.A., Giannelli, G.
Publicado 2019

A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer

por Kelley, R K, Hwang, J, Magbanua, M J M, Watt, L, Beumer, J H, Christner, S M, Baruchel, S, Wu, B, Fong, L, Yeh, B M, Moore, A P, Ko, A H, Korn, W M, Rajpal, S, Park, J W, Tempero, M A, Venook, A P, Bergsland, E K
Publicado 2013